Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 130-138

  Li, Naishi ^a,b   Fu, Jingyuan ^a   Koonen, Debby P ^a   Kuivenhoven, Jan Albert ^a   Snieder, Harold ^a   Hofker, Marten H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Dyslipidemia; HDL cholesterol; Insulin resistance; Triglycerides

Indexed keywords

DYSLIPIDEMIA; HDL-CHOLESTEROL; INSULIN RESISTANCE; TRIGLYCERIDES;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 84893818936     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.013     Document Type: Review

References (84)

1. Meigs J.B. Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 2010, 33:1865-1871.
2. Chen L., Magliano D.J., Zimmet P.Z. The worldwide epidemiology of type 2 diabetes mellitus - present and future perspectives. Nat Rev Endocrinol 2012, 8:228-236.
3. Pan X.R., Hu Y.H., Li G.W., Liu P.A., Bennett P.H., Howard B.V. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and Diabetes Study. Diabetes Care 1993, 16:150-156.
4. Li G., Zhang P., Wang J., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
5. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346:393-403.
6. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
7. Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
8. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEngl J Med 2001, 344:1343-1350.
9. Himsworth H. Diabetes mellitus: its differentiation into insulin sensitive and insulin insensitive types. Lancet 1936, 227:127-130.
10. Reaven G.M., Lerner R.L., Stern M.P., Farquhar J.W. Role of insulin in endogenous hypertriglyceridemia. JClin Invest 1967, 46:1756-1767.
11. Ford S., Bozian R.C., Knowles H.C. Interactions of obesity, and glucose and insulin levels in hypertriglyceridemia. Am J Clin Nutr 1968, 21:904-910.
12. Steiner G., Vranic M. Hyperinsulinemia and hypertriglyceridemia, a vicious cycle with atherogenic potential. Int J Obes 1982, 6(Suppl.1):117-124.
13. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
14. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol 2012, 32:1754-1759.
15. von Eckardstein A., Sibler R.A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011, 22:26-32.
16. Drew B.G., Rye K.A., Duffy S.J., Barter P., Kingwell B.A. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8:237-245.
17. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., Unger R.H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994, 91:10878-10882.
18. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995, 44:863-870.
19. Unger R.H., Scherer P.E. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010, 21:345-352.
20. Wilson P.W., Kannel W.B., Anderson K.M. Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985, 13:1-11.
21. Mineo C., Shaul P.W. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012, 111:1079-1090.
22. Filippatos T.D., Rizos E.C., Tsimihodimos V., Gazi I.F., Tselepis A.D., Elisaf M.S. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids 2013, 48:547-555.
23. von Eckardstein A., Nofer J.R. Frail HDLs and stiff arteries in type 2 diabetes in juveniles. Diabetes 2013, 62:2662-2664.
24. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
25. Chavez J.A., Summers S.A. Aceramide-centric view of insulin resistance. Cell Metab 2012, 15:585-594.
26. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012, 15:635-645.
27. Kraegen E.W., Cooney G.J., Turner N. Muscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction. Proc Natl Acad Sci U S A 2008, 105:7627-7628.
28. Bickerton A.S., Roberts R., Fielding B.A., et al. Preferential uptake of dietary fatty acids in adipose tissue and muscle in the postprandial period. Diabetes 2007, 56:168-176.
29. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008, 9:125-138.
30. Cornier M.A., Dabelea D., Hernandez T.L., et al. The metabolic syndrome. Endocr Rev 2008, 29:777-822.
31. Brunham L.R., Kruit J.K., Verchere C.B., Hayden M.R. Cholesterol in islet dysfunction and type 2 diabetes. JClin Invest 2008, 118:403-408.
32. Rutti S., Ehses J.A., Sibler R.A., Prazak R., Rohrer L., Georgopoulos S. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009, 150:4521-4530.
33. Riserus U., Arnlov J., Berglund L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007, 30:2928-2933.
34. Wilson P.W., Meigs J.B., Sullivan L., et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007, 167:1068-1074.
35. Gupta A.K., Dahlof B., Dobson J., Sever P.S., Wedel H., Poulter N.R. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes trial - blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008, 31:982-988.
36. Giannini C., Santoro N., Caprio S., Kim G., Lartaud D., Shaw M. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care 2011, 34:1869-1874.
37. Wilson P.W., D'Agostino R.B., Fox C.S., Sullivan L.M., Meigs J.B. Type 2 diabetes risk in persons with dysglycemia: the Framingham Offspring Study. Diabetes Res Clin Pract 2011, 92:124-127.
38. Hofker M.H. APOC3 null mutation affects lipoprotein profile APOC3 deficiency: from mice to man. Eur J Hum Genet 2010, 18:1-2.
39. Arca M., Minicocci I., Maranghi M. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. Curr Opin Lipidol 2013, 24:313-320.
40. Mingrone G., Henriksen F.L., Greco A.V., et al. Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes 1999, 48:1258-1263.
41. Holzl B., Iglseder B., Sandhofer A., et al. Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency. Diabetologia 2002, 45:378-384.
42. Goodarzi M.O., Taylor K.D., Guo X., et al. Haplotypes in the lipoprotein lipase gene influence fasting insulin and discovery of a new risk haplotype. JClin Endocrinol Metab 2007, 92:293-296.
43. Goodarzi M.O., Guo X., Taylor K.D., et al. Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Diabetes 2004, 53:214-220.
44. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. NEngl J Med 2010, 362:1082-1089.
45. Robciuc M.R., Maranghi M., Lahikainen A., et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol 2013, 33:1706-1713.
46. Lopez-Rios L., Perez-Jimenez P., Martinez-Quintana E., et al. Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands. Nutr Metab Cardiovasc Dis 2011, 21:18-24.
47. Pihlajamaki J., Karjalainen L., Karhapaa P., et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000, 20:1789-1795.
48. Gomez P., Perez-Jimenez F., Marin C., et al. The -514 C/T polymorphism in the hepatic lipase gene promoter is associated with insulin sensitivity in a healthy young population. JMol Endocrinol 2005, 34:331-338.
49. Stefan N., Schafer S., Machicao F., et al. Liver fat and insulin resistance are independently associated with the -514C>T polymorphism of the hepatic lipase gene. JClin Endocrinol Metab 2005, 90:4238-4243.
50. von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 2006, 186:231-239.
51. Vergeer M., Brunham L.R., Koetsveld J., et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010, 33:869-874.
52. Hegele R.A. Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc Med 2004, 14:133-137.
53. Simha V., Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006, 17:162-169.
54. Hegele R.A., Pollex R.L. Genetic and physiological insights into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2005, 289:R663-R669.
55. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
56. Asselbergs F.W., Guo Y., van Iperen E.P., et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012, 91:823-838.
57. Wolfs M.G., Li N., Fu J., Wijmenga C., van Haeften T.W., Hofker M.H. Genetic insights through genome wide association studies in type 2 diabetes mellitus will lead to new therapeutics. Changing views on living organisms 2013, 210-240. Bentham eBooks. C. Neri (Ed.).
58. Katan M.B. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986, 1:507-508.
59. Smith G.D., Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 2003, 32:1-22.
60. Smith G.D., Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004, 33:30-42.
61. De Silva N.M., Freathy R.M., Palmer T.M., et al. Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes 2011, 60:1008-1018.
62. Qi Q., Liang L., Doria A., Hu F.B., Qi L. Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. Diabetes 2012, 61:745-752.
63. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
64. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
65. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
66. Saito Y. Pitavastatin: an overview. Atheroscler Suppl 2011, 12:271-276.
67. Kawai Y., Sato-Ishida R., Motoyama A., Kajinami K. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Dev Ther 2011, 5:283-297.
68. Tamaki N., Ueno H., Morinaga Y., Shiiya T., Nakazato M. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. JAtheroscler Thromb 2012, 19:532-538.
69. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. JGastroenterol 2011, 46:101-107.
70. Ooi C.P., Loke S.C. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012, 12:CD009361.
71. Rosenson R.S. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006, 185:327-330.
72. Goldfine A.B. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008, 23:502-511.
73. Smushkin G., Sathananthan M., Piccinini F., et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 2013, 62:1094-1101.
74. Marina A.L., Utzschneider K.M., Wright L.A., Montgomery B.K., Marcovina S.M., Kahn S.E. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function. Diabetes Care 2012, 35:1119-1125.
75. Beysen C., Murphy E.J., Deines K., Chan M., Tsang E., Glass A. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012, 55:432-442.
76. Jones I.R., Swai A., Taylor R., Miller M., Laker M.F., Alberti K.G. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990, 13:855-863.
77. Tenenbaum A., Motro M., Fisman E.Z., Schwammenthal E., Adler Y., Goldenberg I. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
78. Tenenbaum A., Fisman E.Z., Boyko V., Benderly M., Tanne D., Haim M. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741.
79. Tenenbaum H., Behar S., Boyko V., Adler Y., Fisman E.Z., Tanne D. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-271.
80. Fabbrini E., Mohammed B.S., Korenblat K.M., Magkos F., McCrea J., Patterson B.W. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. JClin Endocrinol Metab 2010, 95:2727-2735.
81. Bajaj M., Suraamornkul S., Hardies L.J., Glass L., Musi N., DeFronzo R.A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007, 50:1723-1731.
82. Drew B.G., Duffy S.J., Formosa M.F., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111.
83. Barter P.J., Rye K.A., Tardif J.C., et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011, 124:555-562.
84. Schaub M.A., Boyle A.P., Kundaje A., Batzoglou S., Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res 2012, 22:1748-1759.